Company
OncoSil Medical Ltd
ASX:OSL
OncoSil Medical is a global medical device company focused on Interventional Oncology. The company's mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.
61 stories · page 3 of 4
OncoSil Medical completes Fast Track Face-to-Face for CE Mark
The CE Mark is the mandatory regulatory designation required to commercially market and sell the OncoSil™ medical device in the European Union. OncoSil now awaits the final outcome of the review as the Notified Body continues its asse
OncoSil Medical valued at A$0.35 price target: broker
Wilson HTM has initiated coverage on OncoSil Medical with a Speculative Buy rating and a price target of A$0.35. The target is more than double the company's last trading price of $0.15.
OncoSil Medical receives hefty valuation from research firm
OncoSil has received a valuation of A$175-210 million from a European life sciences research group.
OncoSil Medical's device scheduled for CE Mark Fast Track review
A CE Mark is the mandatory regulatory designation required to commercially market and sell OncoSil™ in the European Union. This would be a company-making milestone.
OncoSil Medical Melbourne/Sydney Investor Luncheon Presentation
OncoSil Medical Melbourne/Sydney Investor Luncheon Presentation